Novavax (NasdaqGS:NVAX) FY Conference Transcript

Novavax FY Conference Summary Company Overview - Company: Novavax (NasdaqGS: NVAX) - Event: FY Conference held on March 03, 2026 Key Points Strategic Shift - Novavax has successfully pivoted from being solely focused on COVID-19 to a broader strategy that includes out-licensing its technology and expanding its R&D efforts [4][5] - The company aims to generate data to support its technology and expand the utility of its Matrix-M adjuvant platform, including new formulations like dry powder [4][5] Partnerships and Collaborations - Novavax has established partnerships with major pharmaceutical companies, including Sanofi and Pfizer, to utilize its Matrix technology in their vaccine development [5][6] - The company is seeing increased interest from potential partners, indicating a strong market demand for its technology [6] Upcoming Milestones - Key milestones for 2026 include feedback from Sanofi on clinical trials for combination vaccines and initial steps from Pfizer regarding their selected area for Matrix-M exploration [7][9] - New partnership announcements and data from Novavax's pipeline are also anticipated [9] Market Positioning - Nuvaxovid is well-positioned in the U.S. COVID vaccine market, with Sanofi leading commercialization efforts. The vaccine's tolerability profile is highlighted as a significant advantage [10][11] - Sanofi's proprietary distribution network and their methodical approach to building market share are expected to enhance Nuvaxovid's performance [12] Financial Outlook - Novavax has a strong financial position with a cash runway expected to last into 2028, supported by non-dilutive cash from partnerships and credit facilities [30] - The company aims for non-GAAP profitability by 2028, with potential contributions from milestones and royalties from vaccine sales [31][32] R&D Focus - Novavax is developing a portfolio of new adjuvants to enhance immune responses for difficult-to-treat diseases, including oncology [20][22] - The company is exploring the use of Matrix-M in oncology, emphasizing partnerships rather than becoming an oncology company itself [22] C. difficile Vaccine Development - Novavax is working on a C. difficile vaccine, addressing a significant unmet medical need as there is currently no vaccine on the market [23][24] - Early preclinical data for the C. difficile vaccine is promising, with a focus on generating mucosal immunity and durable immune responses [25][28] Cost Management - The company has significantly reduced its SG&A and R&D expenses from approximately $1.7 billion to a target of $200 million or below by 2028 [33][34] - This lean infrastructure is designed to support multiple partnerships and revenue generation opportunities [34] Future Expectations - Novavax plans to continue building partnerships with various pharmaceutical companies, aiming for multiple revenue streams through royalties and milestones [34][35] - The company is optimistic about achieving its financial and strategic goals, with a focus on transparency in future announcements [35] Conclusion - Novavax is positioned for growth through strategic partnerships, a diversified pipeline, and a strong financial outlook, with a focus on addressing unmet medical needs and achieving profitability by 2028.